SWP
FLNA

Strategic Wealth Partners’s Filana Therapeutics FLNA Stock Holding History

Strategic Wealth Partners’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-275
Closed -$545 – 1546
2025
Q4 		$545 Hold
275
– – ﹤0.01% 1331
2025
Q3 		$800 Hold
275
– – ﹤0.01% 1226
2025
Q2 		$498 Buy
+275
New +$489 ﹤0.01% 1080

Other funds holding FLNA

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Strategic Wealth Partners's FLNA Position: Q1 2026 in Review

Strategic Wealth Partners sold out of Filana Therapeutics (FLNA) in Q1 2026, closing a stake of 275 shares — an estimated $545 sold.

Strategic Wealth Partners first reported a position in FLNA in Q2 2025 and held it in 3 quarters. The position peaked at $800 in Q3 2025. 101 funds tracked by Wall St. Rank hold FLNA as of Q1 2026.

  • Strategic Wealth Partners reported no remaining Filana Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Strategic Wealth Partners sold 275 Filana Therapeutics shares in Q1 2026, an estimated $545.
  • Strategic Wealth Partners first reported a position in Filana Therapeutics in Q2 2025 and held it in 3 quarters.
  • Strategic Wealth Partners's Filana Therapeutics position peaked at $800 in Q3 2025.
  • 101 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2026.

Based on Strategic Wealth Partners's 13F filing for Q1 2026, filed 12 May 2026.